Miscellaneous Urogenital Disorders
The researchers found that during the study period, CKD disability-adjusted life years increased by 52.6%. Death due to CKD increased by 58.3%, from 52,127 to 82,539 deaths.
Patients with uncomplicated urogenital gonorrhea treated with the novel antibiotic zoliflodacin, developed in part due to increasingly antibiotic resistant gonorrhea, were cured at rates similar to that seen in patients treated with ceftriaxone.
"We believe that the data actually suggest possible benefit for ESKD [end-stage kidney disease] with intensive glucose control, and remain inconclusive for intensive blood pressure control and fibrate use given the wide confidence intervals for the more reliable ESKD outcomes," write the authors.
Contepo, an investigational epoxide intravenous (IV) antibiotic, has broad spectrum activity against Gram-negative and Gram-positive pathogens, including multi-drug resistant strains such as ESBL-producing Enterobacteriaceae.
The researchers found that patients received a median monthly iron dose of 264 and 145mg in the high- and low-dose groups, respectively.
UGN-1 is an investigational formulation of mitomycin, delivered to patients using standard intravesical catheters.
The researchers found that by vaccine type, the adjusted rates of first hospitalization were 8.43, 7.88, and 7.99 per 100 patient-months, respectively, and rates for death were 1.00, 0.97, and 1.04, respectively; these differences were not significant.
Among patients with septic shock and acute kidney injury, there was no significant difference in 90-day mortality between early (within 12 hours) and delayed (after 48 hours) initiation of renal-replacement therapy (RRT).
Of the 5256 patients who received a renal transplant in the study window (1/1/1998 - 12/31/2017), 14 met inclusion criteria.
After the second planned interim analysis, the trial was stopped early for futility. The researchers found that 58% of patients in the early-strategy group and 54% in the delayed-strategy group had died (P= 0.38).
Larger proportions of the overall between-facility variation in ICH-CAHPS scores were explained by geographic location and dialysis facility characteristics than patient characteristics.
Using data from the National Health and Nutrition Examination Survey (1999-2010), researchers evaluated caffeine consumption among 4863 non-institutionalized adults with CKD to determine the association between caffeine intake and mortality in these patients.
Patient reported experience has recently been incorporated into Quality Incentive Programs for dialysis centers across the United States. Lower patient experience scores were reported in for-profit, free-standing, and large dialysis organization centers.
During the first 6 hours after receiving the drug, the patient voided 850mL, and pain remained controlled. On ultrasonography, bladder volume was 77mL one day later.
The Dako PD-L1 IHC 22C3 PharmDx Assay has been approved as a companion diagnostic to identify patients with with locally advanced or metastatic urothelial carcinoma who are cisplatin-ineligible for treatment with Keytruda.
A Phase 3 trial (Vista) of the treatment is currently taking place; the trial is evaluating the treatment in patients with NMIBC who have previously received 2 courses of BCG and who are now BCG-unresponsive.
"In summary, this trial provides reassuring (albeit preliminary) evidence that kidneys from HCV-infected donors may be safely transplanted into HCV-negative recipients," the authors write.
The researchers found that stone passage rates were 50% in the tamsulosin group and 47% in the placebo group (relative risk, 1.05; 95.8% confidence interval, 0.87 to 1.27; P=.60).
A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.
Time-dependent metformin use was not associated with incident acidosis overall or in those with eGFR 45 to 59 and 30 to 44 mL/min/1.73 m² (aHR, 1.16 [95% CI, 0.95 to 1.41] and 1.09 [95% CI, 0.83 to 1.44]) compared with alternative diabetes management.
However, there was no significant difference in visceral fat area (P=.32), subcutaneous fat area (P=.36), visceral fat volume (P=.38), or subcutaneous fat volume (P=.23).
"The VFI-based approach allows for the rapid determination of mGFR at the bedside while maintaining patient safety and measurement accuracy and reproducibility," the authors write.
In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks. HbA1c at 26 weeks with a 0.4% non-inferiority margin was designated as the primary outcome, while secondary outcomes included eGFR and urine albumin-to-creatinine ratio.